Financial Performance - Consolidated sales for the three months ended January 31, 2026, were $669,461,000, representing an 8.8% increase from $615,420,000 in the same period of 2025 [82]. - Gross margin improved slightly to 54.7% for the three months ended January 31, 2026, compared to 54.6% in the prior year [85]. - Net income increased by 40.9% to $133,382,000, or $2.38 per diluted share, up from $94,652,000, or $1.65 per diluted share, in the same period of 2025 [90]. - Operating profit rose by 18.1% to $166,405,000 for the three months ended January 31, 2026, compared to $140,947,000 in the prior year [82]. - Segment EBITDA for the Medical and Fluid Solutions segment increased by 3.1% to $70,206,000, driven by favorable mix and strong organic sales growth [86]. Regional Performance - The Asia Pacific region saw a significant organic sales increase of 23.2%, contributing to total sales growth [84]. Cash Flow and Liquidity - Cash and cash equivalents increased by $11,950,000 during the three months ended January 31, 2026 [91]. - The company maintained a strong liquidity position with $120,392,000 in cash on hand and $945,420,000 in available borrowings as of January 31, 2026 [94]. - The company repurchased $86,001,000 in common shares and paid $45,786,000 in dividends during the same period [91]. - Interest expense decreased to $22,741,000 for the three months ended January 31, 2026, down from $25,618,000 in the comparable period of 2025 [88]. Forward-Looking Statements - The company acknowledges the presence of forward-looking statements that may involve risks and uncertainties, including economic and political conditions, market conditions, and potential acquisitions [95]. - Actual results may differ significantly from expected results due to various factors, and readers are cautioned against placing undue reliance on forward-looking statements [96]. - The company has disclosed information regarding financial instruments sensitive to interest rates and foreign currency exchange rates, which has not changed materially since the last report [98].
Nordson(NDSN) - 2026 Q1 - Quarterly Report